UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 382

Sortiert nach

Folate-Targeted Cholesterol-Grafted Lipo-Polymeric Nanoparticles for Chemotherapeutic Agent Delivery

AAPS PharmSciTech, 2020-10, Vol.21 (7), p.280, Article 280

2020

Volltextzugriff (PDF)

Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer

BMC cancer, 2021-12, Vol.21 (1), p.1316-1316, Article 1316

2021

Volltextzugriff (PDF)

miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1

Molecular cancer, 2016-11, Vol.15 (1), p.70, Article 70

2016

Volltextzugriff (PDF)

Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel

Acta pharmacologica Sinica, 2021-12, Vol.42 (12), p.2132-2143

2021

Volltextzugriff (PDF)

Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial

BMC cancer, 2022-02, Vol.22 (1), p.177-9, Article 177

2022

Volltextzugriff (PDF)

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer

BMC cancer, 2021-11, Vol.21 (1), p.1281-1281, Article 1281

2021

Volltextzugriff (PDF)

Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer

Nature communications, 2021-02, Vol.12 (1), p.723-723, Article 723

2021

Volltextzugriff (PDF)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?

BMC cancer, 2018-10, Vol.18 (1), p.987-987, Article 987

2018

Volltextzugriff (PDF)

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma

BMC cancer, 2018-12, Vol.18 (1), p.1279-1279, Article 1279

2018

Volltextzugriff (PDF)

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Clinical drug investigation, 2020-02, Vol.40 (2), p.129-137

2020

Volltextzugriff (PDF)

Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study

BMC cancer, 2019-07, Vol.19 (1), p.725-725, Article 725

2019

Volltextzugriff (PDF)

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

Nature communications, 2018-07, Vol.9 (1), p.2897-18, Article 2897

2018

Volltextzugriff (PDF)

Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression

BMC cancer, 2018-07, Vol.18 (1), p.718-718, Article 718

2018

Volltextzugriff (PDF)

The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

BMC cancer, 2022-01, Vol.22 (1), p.104-104, Article 104

2022

Volltextzugriff (PDF)

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Breast cancer research : BCR, 2023-06, Vol.25 (1), p.62-62, Article 62

2023

Volltextzugriff (PDF)

Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells

BMC cancer, 2019-01, Vol.19 (1), p.27-27, Article 27

2019

Volltextzugriff (PDF)

SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis

Nature communications, 2021-03, Vol.12 (1), p.1812-14, Article 1812

2021

Volltextzugriff (PDF)

JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance

BMC cancer, 2023-05, Vol.23 (1), p.423-423, Article 423

2023

Volltextzugriff (PDF)

Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)

BMC cancer, 2023-04, Vol.23 (1), p.308-308, Article 308

2023

Volltextzugriff (PDF)

Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties

Acta pharmacologica Sinica, 2019-05, Vol.40 (5), p.689-698

2019

Volltextzugriff (PDF)

Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer

Nature communications, 2020-11, Vol.11 (1), p.6093-8, Article 6093

2020

Volltextzugriff (PDF)

Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1

Molecular cancer, 2020-02, Vol.19 (1), p.33-33, Article 33

2020

Volltextzugriff (PDF)

Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study

BMC cancer, 2020-09, Vol.20 (1), p.832-9, Article 832

2020

Volltextzugriff (PDF)

Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer

Nature communications, 2021-03, Vol.12 (1), p.1714-21, Article 1714

2021

Volltextzugriff (PDF)

1 – 25 von 382

Suche als RSS-Feed

Aktive Filter

SpracheNorwegisch

KollektionNexis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(258)
Mit Volltextzugriff
(310)

Publikationsform

Sprache

Englisch
(382)
Japanisch
(33)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Folate-Targeted Cholesterol-Grafted Lipo-Polymeric Nanoparticles for Chemotherapeutic Agent Delivery

Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer

miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1

Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel

Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer

Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression

The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells

SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis

JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance

Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties

Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer

Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1

Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study

Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer

Aktive Filter

Suchergebnisse filtern